Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy

por Chin, K., Chand, V. K., Nuyten, D. S. A.
Publicado 2017

No common denominator for breast cancer lymph node metastasis

por Weigelt, B, Wessels, L F A, Bosma, A J, Glas, A M, Nuyten, D S A, He, Y D, Dai, H, Peterse, J L, van't Veer, L J
Publicado 2005

Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types

por Starmans, M H W, Krishnapuram, B, Steck, H, Horlings, H, Nuyten, D S A, van de Vijver, M J, Seigneuric, R, Buffa, F M, Harris, A L, Wouters, B G, Lambin, P
Publicado 2008

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced...

por Garrett, C R, Siu, L L, El-Khoueiry, A, Buter, J, Rocha-Lima, C M, Marshall, J, LoRusso, P, Major, P, Chemidlin, J, Mokliatchouk, O, Velasquez, L, Hayes, W, Feltquate, D, Syed, S, Ford, S, Kollia, G, Galbraith, S, Nuyten, D S A
Publicado 2011